RxDoctor Payments Data

Luis Cisneros, MD

Infectious Disease · San Antonio, TXNPI 1235129263

Payments from drug & device makers

$6,447in general payments, 2019–2025

Across 50 payments — averaging $128.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • Janssen Products, LP$99
  • Melinta Therapeutics, LLC$93
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$84
  • Viiv Healthcare Company$80
  • Merck$38
  • plus $66 from 3 others

What the payments were for

  • Consulting fees$4,18065%
  • Travel & lodging$1,08617%
  • Food & beverage$1,04416%
  • Education$1372%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,447 in reported general payments places this provider in the 75th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$99,777
Medicare patients
326
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen198$835,794
BiktarvyBictegrav/Emtricit/Tenofov Ala202$829,420
JulucaDolutegravir/Rilpivirine153$587,015
PrezcobixDarunavir/Cobicistat150$408,024
TivicayDolutegravir Sodium111$288,820
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$122,332
DescovyEmtricitabine/Tenofov Alafenam38$91,135
DovatoDolutegravir Sodium/Lamivudine12$41,479
IsentressRaltegravir Potassium14$32,452
Etravirine24$25,367
EdurantRilpivirine Hcl14$23,510
Darunavir25$21,287
Ritonavir19$5,570
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam11$1,477
Abacavir-LamivudineAbacavir Sulfate/Lamivudine13$1,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$5,987$1,756,350438 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato$80$917,314276 claims
Johnson & JohnsonPrezcobix$19$408,024150 claims
MerckIsentress$38$32,45214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 576 infectious disease providers in Texas.

Other infectious disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →